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Abstract
Background: There is increased risk of cardiovascular disease among HIV seropositive individuals. The prevalence of HIV is
highest in sub-Saharan Africa; however, HIV-related cardiovascular risk research is largely derived from developed country
settings. Herein, we describe the prevalence of hypertension and obesity in a large HIV treatment program in Kenya.
Methods: We performed a retrospective analysis of the electronic medical records of a large HIV treatment program in
Western Kenya between 2006 and 2009. We calculated the prevalence of hypertension and obesity among HIV+ adults as
well as utilized multiple logistic regression analyses to examine the relationship between clinical characteristics, HIV-related
characteristics, and hypertension.
Results: Our final sample size was 12,194. The median systolic/diastolic blood pressures were similar for both sexes (male:
110/70 mmHg, female: 110/70 mmHg). The prevalence of hypertension among men and women were 11.2% and 7.4%,
respectively. Eleven percent of men and 22.6% of women were overweight/obese (body mass index $25 kg/m
2). Ordinal
logistic regression analyses showed that overweight/obesity was more strongly associated with hypertension among HIV+
men (OR 2.41, 95% CI 1.88–3.09) than a higher successive age category (OR 1.62, 95% CI 1.40–1.87 comparing 16–35, 36–45
and .45 years categories). Among women, higher age category and overweight/obesity were most strongly associated
with hypertension (age category: OR 2.21, 95% CI 1.95–2.50, overweight/obesity: OR 1.80, 95% CI 1.50–2.16). Length of time
on protease inhibitors was not found to be related to hypertension for men (OR 1.62, 95% CI 0.42–6.20) or women (OR 1.17,
95% CI 0.37–2.65) after adjustment for CD4 count, age and BMI.
Conclusion: In Western Kenya, there is a high prevalence of hypertension and overweight/obesity among HIV+ patients
with differences observed between men and women. The care of HIV+ patients in sub-Saharan Africa should also include
both identification and management of associated cardiovascular risk factors.
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Introduction
The currently available evidence suggests that there is an excess
risk of cardiovascular disease (CVD) among human immunode-
ficiency virus (HIV) seropositive (+) compared to HIV seronegative
(2) individuals [1]. HIV+ patients are at an elevated risk of
developing dyslipidemia, carotid atherosclerosis, large vessel
vascular disease, coronary calcification, and coronary artery
disease with or without anti-retroviral therapy [2,3,4,5]. It has
been suggested that of the many factors that are involved in the
development of CVD in HIV+ patients, traditional cardiovascular
risk factors are the main contributors [6]. The few studies
evaluating the prevalence of traditional cardiovascular risk factors
among HIV+ patients in sub-Saharan Africa suggest that rates are
significantly lower than in developed countries but some of this
difference may be attributed to underdetection based on low
clinical suspicion and small sample sizes [7,8,9]. Large interna-
tional studies have also implicated the HIV itself and anti-
retroviral therapy (ART) as potential mediators of this increased
risk of CVD [10,11,12,13]. These studies, however, have not
included patients from sub-Saharan Africa.
The impact of the HIV/AIDS epidemic has been the greatest in
sub-Saharan Africa with 67% (22.1 million) of all people infected
with HIV worldwide residing in sub-Saharan Africa and the
majority of deaths globally due to HIV occurring in this region [14].
Concurrently, the epidemiology and demography of sub-Saharan
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22288Africa is shifting towards older populations witha higher proportion
of CVD due to chronic, non-communicable diseases [15]. Despite
these facts, the region is under-represented in studies examining the
relationship betweenHIVand CVDrisk factors. Understanding the
distribution of cardiovascular risk factors among HIV+ patients in
sub-Saharan Africa is important due to the known cardiovascular
effects of HIV and its treatment, and the exceedingly high
prevalence of HIV in this region. Furthermore, global efforts in
sub-Saharan Africa aimed solely at HIV care may be missing a
critical opportunity to improve overall cardiovascular health if
chronic CVD risk factors are highly prevalent. The objective of this
study was to describe the prevalence of hypertension, overweight/
obesity and HIV-related cardiovascular risk factors in a large HIV
treatment program in Western Kenya.
Methods
Ethics Statement
This retrospective study used de-identified data from the
electronic medical records of HIV+ adult patients treated in the
Academic Model Providing Access to Healthcare (AMPATH)
program. Individual informed consent was not obtained. The
Institutional Research and Ethics Committee of the Moi
University School of Medicine and the Institutional Review
Boards of Indiana, Duke and Brown Universities approved use of
these data and waiver of informed consent.
Study Site & Population
The AMPATH (previously an acronym for Academic Model for
the Prevention and Treatment of HIV/AIDS) clinical care system
was created in 2001 and has been described previously [16,17].
AMPATH now provides HIV care and treatment to over 50,000
adults and children living with HIV/AIDS in 19 clinics
throughout western Kenya. Patients are managed according to
National Kenyan protocols, which are consistent with World
Health Organization guidelines. Clinic visits occur monthly for all
patients on ART unless alternative arrangements have been made
with their health care provider. Patients who are not yet eligible
for treatment are seen monthly or bi-monthly depending on their
immunologic status and other factors in their health profile.
Standard paper data collection forms are used at enrollment to the
program and at each subsequent visit. Data from these forms are
entered into the AMPATH electronic Medical Record System by
data entry technicians [18]. Blood pressure was measured during a
clinical encounter and was commonly performed using a manual
sphygmomanometer by a trained nurse. Height and weight were
also measured as part of routine HIV care. The anthropometric
measurements were not measured according to a standard
protocol but were performed as a part of routine clinical care.
We included in this analysis HIV+ patients ages 16 to 80 years
who wereenrolled in the AMPATHprogram between September 1,
2006 and March 5, 2009. We excluded patients for whom only one
or no blood pressure readings were recorded during the study period
or who were pregnant during this time period. We further restricted
our sample to those patients with available data height, weight, heart
rate and CD4 count during the follow-up period. Clinical and
laboratory data for each patient (blood pressure, weight, height,
heart rate, creatinine) were drawn from the most recently available
patient encounter for each variable separately. We included CD4
counts within 6 months of the last follow-up date in the analyses.
There were 47,360 patients who were enrolled in the AMPATH
programduring thestudyperiod.Of these,32,546wereexcludedfor
the following reasons: 8,661 women were pregnant and 23,885 had
insufficient blood pressure recordings during the study period. After
applying inclusion and exclusion criteria, there were 14,814 patients.
There were 437 patients (126 male, 311 female) who had data that
were considered out of acceptable range for at least one of the key
data elements and therefore not included, using the following
criteria: systolic blood pressure (SBP),65 or .220 mmHg, diastolic
blood pressure (DBP),40 or .120 mmHg, body mass index
(BMI),15 or .40 kg/m
2, heart rate ,40 or .230 beats per
minute. There were 2,040 patients (707 male, 1,333 female) who
were missing data for CD4 count, pulse or BMI and were excluded
from the analysis. There were 143 patients who had values that were
out of range for one of the key data elements as well as data missing
for anotherkeydataelement. A total of 2,620patients were excluded
due to missing data or data that was out of range. After applying
inclusion and exclusion criteria, our final analysis consisted of 12,194
individuals. (Figure 1)
Variable Definitions and Statistical Analysis
PrehypertensionwasdefinedasSBP120–139 mmHgorDBP80–
89 mmHg. Hypertension was defined as SBP$140 mmHg or
DBP$90 mmHg as of the most recent patient encounter. Use of
protease inhibitors (PIs) was defined as being prescribed any of the
locally available PIs which include lopinavir, ritonavir or darunavir.
BMI was defined and categorized according to standard interna-
tional definitions [19]. Creatinine measurements in micromoles per
liter were converted to milligrams per deciliter by dividing by 88.4.
Glomerular filtration rate was estimated using the abbreviated
Modified Diet inRenalDisease equation[20].Wecreated a variable
that represented the sum total cardiovascular risk that assigns one
point for each of the following risk factors: SBP$140 mmHg,
DBP$90 mmHg and BMI$25 kg/m
2, yielding a maximum value
of 3. For the analyses including use of PIs, the sample sizes used were
smaller due to a smaller number of patients for whom these data
were available. Descriptive analyses were performed to display the
overall distribution of the cardiovascular, clinical and HIV-related
risk factors for men and women. Continuous variables are displayed
as median (interquartile range) for our descriptive analyses and
categorical variables are expressed as proportions.
Our analyses are designed to meet two goals: first, to describe
the distribution of individual CVD risk factors over a joint
categorization of age and CD4 count (using categories defined
above); and second, to model the variation in CVD risk as a
function of age, CD4 count, BMI, and duration of PI usage. Our
analyses are stratified by gender.
To meet the first objective, we generated tables of mean SBP,
DBP, BMI, and days on PI, and prevalence of hypertension,
jointly stratified by CD4 category (CD4,200, 200#CD4#350,
CD4.350) and age category (16#age#35, 35,age#45, age.45
years). These age categories were based on the age distribution
and life expectancy in Kenya (54 years in 2007) [21] and then
selected by extrapolation to select the middle and older age cut-
offs. We used the Kruskal-Wallis test to compare the distributions
of SBP, DBP, BMI and duration of PI use across CD4 count
categories within each age category. The Chi Square test was used
to test for homogeneity of proportions of hypertensive subjects
across CD4 categories within each age category. The Cochran-
Armitage test was used to test for trend across SBP, DBP, BMI,
duration of PI use and proportion of hypertensive subjects across
CD4 count categories within each age category.
For a more concise summary of these associations, and to test
hypotheses about factors associated with CVD risk, we used regression-
based analyses. First, we used ordinal logistic regression models to
model cardiovascular risk (range 0–3) as a function of CD4 count and
age. Secondly, we used standard logistic regression to model the
individual risk factors DBP$90 mmHg, SBP$140 mmHg, and HTN
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separately for men and women. In the regression models, age was
analyzed as three ordinal categories such that the odds ratios reflect the
change in odds for one successively higher age category. CD4 count
was categorized as: $200 or ,200 cells/mm
3,a n dB M Ia s$25 or
,25 kg/m
2. For the subset of patients prescribed PIs, we fit the same
regressions described above but added use of PIs$5 4 0d a y sa sa
covariate [12,22].
Using thresholds for SBP ($140 mmHg), DBP ($90 mmHg),
BMI ($25 kg/m
2), and length of time using PIs ($540 days) we
calculated the proportions of individuals exceeding the thresholds.
Results
Baseline descriptive characteristics are shown in Table 1. The
median (IQR) age was 43 (37–49) and 40 (34–47) years for men
and women, respectively. Median SBP, DBP and BMI were
similar between men (110 mmHg, 70 mmHg and 20.8 kg/m
2)
and women (110 mmHg, 70 mmHg and 22.0 Kg/m
2), respec-
tively. Prehypertension was present in 765 (17.8%) men and 1,075
(13.6%) women. Hypertension was present in 481 (11.2%) men
and 583 (7.4%) women. Using a BMI threshold of $25 kg/m
2,
453 (10.6%) men and 1,782 (22.6%) women were overweight/
obese. A small number of men (226) and women (295) were
prescribed a PI drug during this time period. Among patients
taking PIs, the prevalences of overweight/obesity among men and
women were 14.6% and 22.0%, respectively. In the subgroup of
patients taking PIs, hypertension was present in 10.2% of men and
8.8% of women. Among patients who had been prescribed PIs,
54.4% of men and 54.6% of women had been taking a drug in this
class for greater than 540 days.
Table 2 shows the distribution of cardiovascular risk and clinical
factorswithinCD4count and acrossagecategories formen.Among
men, SBP was progressively higher among patients with a CD4
count .350 compared to those with a CD4 count 200–350 and
,200 for the 16–35 years group (Cochrane-Armitage test for trend,
p,0.05) and the 36–45 years group (p,0.05) but not in the .45
years group (p=0.34). There were no clinically significant
differences seen in DBP with higher CD4 category. There was a
modest statistically significant higher BMI present in individuals
with higher CD4 counts within each age category. The prevalence
of hypertension tended to be higher among individuals with higher
CD4 counts in the youngest age group, but not in the two older
groups. The prevalence of hypertension was 6 times greater among
men aged 16–35 years with CD4 greater than 200–350 compared
to men with lower CD4 counts (1.4% vs. 7.8%, p=0.02). Blood
pressure was higher, in general, among men who were older.
Table 3 shows the distribution of cardiovascular risk and clinical
factorswithin CD4 count and across age categories forwomen.Among
women, SBP was significantly higher in each successively higher CD4
count category for each age category (Table 3). There were no
clinically significant differences in BMI or DBP across CD4 categories.
The prevalence of hypertension was not significantly higher among
women with higher CD4 counts in any of the age categories. As,
expected blood pressure was higher among women who were older.
Variables associated with greater number of cardiovascular risk
factors were entered into logistic regression models for men and
women separately using number of risk factors and measures of
hypertension as the outcome variables (Table 4). In an age-adjusted
model, CD4 count above 200 was positively associated with a
greaternumberofcardiovascular risk factors inmen (OR 1.34,95%
CI 1.10–1.63) and in women (OR 1.48, 95% CI 1.26–1.73). After
Figure 1. Analysis profile. The records of all patients enrolled in the AMPATH program between September 1, 2006 and March 5, 2009 were
screened for inclusion and exclusion criteria described in the text. We also excluded patients who were missing data for any of the following
elements: CD4 count, heart rate, height or weight. We also excluded patients who had vital data, which was thought to be out of acceptable range.
Acceptable ranges were defined as: SBP.65 and ,220 mmHg, DBP.40 and ,120 mmHg, BMI.15 and ,40 kg/m2 and heart rate .40 and ,230
beats per minute. Some records could have had missing values for one variable and out of range for another. A total of 2,620 records were excluded
for out of range or missing data yielding 12,194 records in the final analysis.
doi:10.1371/journal.pone.0022288.g001
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Men Women
n=4,293 (35.2%) n=7,901 (64.8%)
Median (IQR) or n (%) Median (IQR) or n (%)
Demographic and Clinical Characteristics
Age (years) 43 40
(37–49) (34–47)
Systolic BP (mm Hg) 110 110
(100–120) (100–120)
Diastolic BP (mm Hg) 70 70
(60–80) (60–76)
Pulse (beats per minute) 80 84
(70–91) (75–94)
Height (Meters) 1.7 1.6
(1.6–1.8) (1.5–1.7)
Weight (Kg) 62 59
(57–69) (52–66)
BMI (Kg/m
2)2 1 2 2
(19–23) (20–25)
Creatinine (mmol/L)
1 74 59
(63–86) (51–69)
eGFR (mL/min per 1.73 m
2)
1 129 125
(108–155) (104–150)
Urban 2,199 3,747
(51.2) (47.4)
Stage 3 CKD or Worse
1 34 47
(2.3) (1.9)
Death or lost to follow up 1,114 1,961
(26.0) (24.8)
HIV-Related Characteristics
CD4 (count per mm
3) 338 405
(223–468) (272–545)
On ART 3,091 4,960
(72.0) (62.8)
Use of PI
??? 226 295
(5.3) (3.7)
Length on PI of those on PIs (days) 612 609
(261–854) (261–861)
Time on PI.540 of those on PIs (days) 123 161
(54.4) (54.6)
Cardiovascular (CV) Risk Factors
Prehypertension* 765 1,075
(18%) (14%)
Hypertension
" 481 583
(11%) (7%)
SBP$140 mm Hg 392 453
(9.1%) (5.7%)
DBP$90 mm Hg 262 365
(6%) (5%)
Overweight/Obese 453 1,782
(11%) (23%)
Number of CV risk factors
6
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ncluding overweight/obesity into the model, the odds of having
hypertension weregreaterthan two timeshigherinmenif they were
overweight/obese (OR 2.41, 95% CI 1.88–3.09) while the
relationship between CD4 count and hypertension had a smaller
estimate of effect and was not statistically significant (OR 1.23, 95%
CI 0.95–1.58). A similar positive relationship existed between
overweight/obesity and both SBP and DBP independently. Among
women, age (OR 2.21, 95% CI 1.95–2.50) and being overweight/
obese (OR 1.80, 95% CI 1.50–2.16) were most strongly associated
with having hypertension. Being overweight/obese almost doubled
theoddsthatawomanwouldhavehypertension.Age,however,was
the strongest predictor of hypertension or SBP$140 mmHg (OR
2.42, 95% CI 2.10–2.80) in the fully adjusted model.
In subsequent models, we restricted our analyses to only patients
who were prescribed PIs (Table 5). Length of time on PIs$540
days was not found to be significantly associated with higher SBP,
DBP, hypertension or greater number of cardiovascular risk
factors. Of the four variables included in the logistic regression
models using blood pressure as the outcome, overweight/obesity
was the strongest predictor of hypertension and higher SBP.
Discussion
Cardiovascular diseases are a widely recognized complication of
HIV infection [23]. Very few studies of the distribution of
cardiovascular risk factors among HIV+ individuals have examined
Men Women
n=4,293 (35.2%) n=7,901 (64.8%)
Median (IQR) or n (%) Median (IQR) or n (%)
One 600 1,817
(14%) (23%)
Two 192 258
(5%) (3%)
Three 41 89
(1%) (1%)
At least 1 CV Risk Factor 833 2,164
(19%) (27%)
BP: blood pressure. BMI: body mass index. eGFR: estimated glomerular filtration rate. CKD: chronic kidney disease. PI: protease inhibitor. ART: anti-retroviral therapy.
1The sample size was smaller for males (n=1,471) and females (n=2,494).
???The sample size was smaller for males (n=3,078) and females (n=4,932).
*Prehypertension is defined as SBP 120–139 mmHg or DBP 80–89 mmHg.
"Hypertension is defined as SBP$140 mmHg or DBP$90 mmHg. Use of anti-hypertensive medications was not routinely assessed. Overweight/Obese is defined as
BMI$25 kg/m
2.
6Based on the following factors: SBP$140 mmHg, DBP$90 mmHg and BMI$25 kg/m
2.
doi:10.1371/journal.pone.0022288.t001
Table 1. Cont.
Table 2. Prevalence of Cardiovascular Risk Factors Stratified by CD4 count and Age among Men, mean (SD) or %.
CD4,200 CD4 200–350 CD4.350
(n=868) (n=1,400) (n=2,025)
Age in years Age in years Age in years
Risk Factor 16–35 36–45 .45 16–35 36–45 .45 16–35 36–45 .45
(n=144) (n=360) (n=364) (n=208) (n=582) (n=610) (n=383) (n=818) (n=824)
SBP, mmHg 110* 113* 117 114 115 118 114 115 118
(12) (15) (17) (15) (15) (18) (13) (13) (17)
DBP, mmHg 67 70 70 69 70 72 69 71 72
(9) (10) (11) (9) (10) (11) (10) (10) (11)
BMI, kg/m
2 20.4
" 20.5
" 20.6
" 20.9 21.0 21.5 21.1 21.5 21.5
(2.6) (3.0) (3.1) (2.8) (2.8) (3.2) (2.6) (3.0) (3.3)
Days on PI 258 417* 461 223 382 606 609 658 597
(224) (322) (347) (287) (358) (319) (417) (311) (334)
Hypertension 1* 9 13 8 9 16 8 9 16
*p,0.05 comparing trend across each CD4 count category within an age category.
"p,0.01 comparing trend across each CD4 count category within an age category.
doi:10.1371/journal.pone.0022288.t002
Hypertension and Obesity in Kenyans with HIV
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e22288sub-Saharan African populations. We have found an 11.2%
prevalence of hypertension among Kenyan HIV+ men and 7.4%
prevalence among Kenyan HIV+ women. Overweight/obesity was
also prevalent among men (10.6%) but higher among women (22.6%).
These data, to our knowledge, represent the first report of CVD risk
factors from an HIV cohort of this size in sub-Saharan Africa.
Hypertension and HIV
With respect to hypertension among HIV+ individuals, little is
known of the epidemiology in sub-Saharan Africa. Developed
country studies suggest the prevalence of hypertension in HIV+
individuals is between 8 and 39% [24,25]. Our prevalence
estimates may be lower than reported in developed countries due
to the low population rate of hypertension in the region. The most
recent population based hypertension prevalence data for Kenya
are from 1987 and suggest a rate between 1.2% and 2.2% [26]. If
the population estimates reflect the true prevalence in the
population, our findings would suggest a higher than expected
rate of hypertension among Kenyan HIV+ individuals. This is
consistent with observations that HIV can have effects on the
vasculature of infected individuals at a relatively young age [27].
To put our findings in context would require a contemporary
analysis of the prevalence of hypertension in Western Kenya.
The relationship between immune system function and
hypertension in HIV+ individuals continues to be the subject of
ongoing investigation [28]. Two large studies have suggested an
association between a lower CD4 count and incident cardiovas-
cular events [11,29]. This relationship is posited to be mediated by
a chronic pro-inflammatory state which promotes atherosclerosis
[30]. However, individual cardiovascular risk is usually deter-
mined by a combination of several risk factors including age,
family history, smoking, hypertension, overweight, diabetes and
Table 4. Factors associated with higher levels of cardiovascular risk.
Men (n=4293)
Number of Risk Factors HTN* SBP$140 mmHg DBP$90 mmHg
Age 1.58 (1.41–1.76) 1.62 (1.40–1.87) 1.77 (1.50–2.08) 1.50 (1.24–1.81)
CD4 Count $200 1.34 (1.10–1.63) 1.23 (0.95–1.58) 1.12 (0.86–1.48) 1.19 (0.86–1.66)
BMI$25 kg/m
2 - 2.41 (1.88–3.09) 2.35 (1.79–3.07) 2.50 (1.83–3.41)
Women (n=7901)
Number of Risk Factors HTN SBP$140 mmHg DBP$90 mmHg
Age 1.38 (1.26–1.48) 2.21 (1.95–2.50) 2.42 (2.10–2.80) 2.04 (1.76–2.39)
CD4 Count $200 1.48 (1.26–1.73) 1.54 (1.15–2.07) 1.50 (1.08–2.09) 1.60(1.10–2.33)
BMI$25 kg/m
2 - 1.80 (1.50–2.16) 1.72 (1.40–2.11) 2.0 (1.60–2.50)
Age is a categorical variable defined by three age categories: 16–35, 36–45 and ,45 years.
CD4 count is a binary variable: $200 and ,200 cells/mm
3.
BMI was not included as a covariate in the risk factor analysis because BMI$25 kg/m
2 is one of the cardiovascular risk factors.
*HTN: hypertension.
doi:10.1371/journal.pone.0022288.t004
Table 3. Prevalence of Cardiovascular Risk Factors Stratified by CD4 count and Age among Women, mean (SD) or %.
CD4,200 CD4 200–350 CD4.350
(n=1068) (n=2,074) (n=4,759)
Age in years Age in years Age in years
Risk Factor 16–35 36–45 .45 16–35 36–45 .45 16–35 36–45 .45
(n=313) (n=453) (n=302) (n=570) (n=839) (n=665) (n=1,338) (n=1,925) (n=1,496)
SBP, mmHg 108
" 109
" 113* 109 112 115 110 112 116
(12) (13) (16) (12) (14) (19) (11) (13) (17)
DBP, mmHg 67 68
" 70 68 69 71 68 69 71
(9) (9) (11) (9) (10) (12) (9) (9) (11)
BMI, kg/m
2 21.4
" 21.8
" 22.2
" 22.3 22.4 22.3 22.5 22.8 22.9
(3.4) (3.7) (4.2) (3.7) (3.8) (3.9) (3.7) (3.9) (4.2)
Days on PI 296 389
" 326
" 351 424 555 347 597 622
(293) (335) (299) (345) (325) (341) (370) (343) (343)
Hypertension 2 3 10 4 7 15 3 6 13
*p,0.05 comparing trend across each CD4 count category within an age category.
"p,0.01 comparing trend across each CD4 count category within an age category.
doi:10.1371/journal.pone.0022288.t003
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system function as measured by a higher CD4 count is related to
higher blood pressure [31]. The pathophysiology in this case has
not been well established but is thought to be due to improved
overall general health and nutritional status [32]. Obesity has also
been implicated as a potential confounder [32,33]. In general,
however, the literature on the relationship between immune
function and blood pressure in HIV+ individuals has mostly
emphasized the impact of class of ART [34,35,36]. In the present
analysis, the relationship between higher CD4 count and higher
prevalence of hypertension was most dramatic among young men
while the relationship between CD4 count and hypertension
seemed blunted among the older age groups. One possible
explanation is that the specific effects of HIV on the vascular
system are most noticeable in patients with few other traditional
cardiovascular risk factors. Indeed, hypertension is more common
among young people with HIV [25]. As age increases, the
attributable effects of HIV on the vascular system may be smaller
than the effects of age or other factors.
Overweight/Obesity and HIV
We have found that one of every ten HIV+ Kenyan men in our
sample was overweight/obese and that overweight/obesity was a
stronger predictor of hypertension than age. Findings from
developed countries suggest that PI use may be driving both
hypertension and obesity [37]. However, in contrast to studies
from developed countries, it is unlikely that use of protease
inhibitors were a major cause of obesity in our sample since the
proportion of people using PIs was low (6.5%). Moreover, our
logistic regression analyses failed to show a precise relationship
between length of time taking PIs and hypertension. Instead,
metabolic disturbances related to HIV infection, other ART
regimens, diet or other factors may be responsible.
The prevalence of overweight/obesity among women in this
analysis is similar to that of women in the general Kenyan
population [38]. However, it is not clear that, in the general
population of black women, overweight/obesity has a consistent
deleterious effect. Historically, black women do not have the same
risk of death associated with obesity as women of other ethnic
groups [39] despite higher rates of diabetes and hypertension
among black women [40]. It has also been suggested that
overweight/obesity is beneficial and is associated with a lower
risk of death among HIV+ women [41]. In the modern era, due to
an epidemiologic transition in sub-Saharan Africa, it is reasonable
to expect that the type and consequences of fat distribution seen in
African HIV+ women may be different from those previously
reported [42]. While overweight/obesity among HIV+ women is
not strongly related to hypertension in our cross-sectional analysis,
the long-term clinical effects of overweight/obesity in HIV should
be studied with attention to sex-based differences.
Protease inhibitors and HTN
Protease inhibitor therapy is known to have cardiovascular
consequences and CVD risk is greatest with prolonged ($540
days) exposure [11,12]. However, in our multivariate regression
analyses adjusted for age and CD4 count, the estimated
association between a longer duration on PIs and higher
cardiovascular risk included the null. This finding does not
support an independent relationship between PI use and higher
cardiovascular risk. Regarding the relationship between PI therapy
and elevated blood pressure, we also do not find a precise
statistically significant relationship. Use of PIs is related to greater
risk of myocardial infarction in large studies [12,13] and our lack
of an association between PI use and number of CVD risk factors
may have been due to small sample size or the lack of data on
cardiovascular events. Among patients on PIs, we did find a
significant relationship between overweight/obesity and higher
blood pressure as there is in the general population and in HIV+
patients in developed countries [33] suggesting that the relation-
ship between hypertension and weight is also preserved among
those on PIs. Longitudinal data on cardiovascular events among
patients on PIs in Kenya, would be necessary to identify whether a
relationship exists between PI use and CVD in this region and to
clarify the effect of overweight/obesity or other factors on CVD in
this subgroup.
There are several limitations within this analysis that deserve
mention. This was a retrospective analysis of clinical data and the
variables of interest were not routinely measured in standard,
Table 5. Factors associated with higher levels of cardiovascular risk among patients using protease inhibitors.
Men (n=226)
Number of Risk Factors HTN* SBP$140 mmHg DBP$90 mmHg
Age 1.51 (0.88–2.60) 1.80 (0.81–3.98) 1.99 (0.81–4.91) 1.99(0.69–5.79)
CD4 Count $200 2.47 (1.21–5.07) 1.17 (0.42–3.26) 1.35 (0.43–4.24) 0.62(0.16–2.35)
Days on PI$540 1.66 (0.80–3.43) 1.82 (0.63–5.27) 1.62 (0.50–5.20) 1.62(0.42–6.20)
BMI$25 kg/m
2 - 4.92 (1.83–13.21) 5.43 (1.89–15.58) 5.91 (1.67–20.89)
Women (n=295)
Number of Risk Factors HTN SBP$140 mmHg DBP$90 mmHg
Age 1.61 (1.10–2.38) 2.84 (1.35–5.96) 2.64 (1.21–5.78) 2.45 (0.98–6.11)
CD4 Count $200 2.10 (1.11–3.97) 1.32 (0.44–3.99) 1.05 (0.34–3.25) 5.57(0.69–45.18)
Days on PI$540 1.09 (0.62–1.90) 1.18 (0.47–2.98) 1.13 (0.42–3.04) 1.17 (0.37–2.65)
BMI$25 Kg/m
2 - 3.32 (1.39–7.94) 3.26 (1.28–8.33) 2.28 (0.79–6.58)
Age is a categorical variable defined by three age categories: 16–35, 36–45 and ,45 years.
CD4 count is a binary variable: $200 and ,200 cells/mm
3.
BMI was not included as a covariate in the risk factor analysis because BMI$25 kg/m
2 is one of the cardiovascular risk factors.
*HTN: hypertension.
doi:10.1371/journal.pone.0022288.t005
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selection bias potentially introduced at the time of the clinical
encounter in that only patients who were able to come to clinic
visits were included in this analysis. As a result we may have
overestimated the prevalence of hypertension in this population
because blood pressure is more likely to have been measured in
patients suspected to have high blood pressure. A large number of
participants were excluded from the analysis due to having too few
measures of blood pressure during the follow-up period which
limits the external validity of our findings and is related to the
retrospective nature of the study design. Another limitation of this
analysis is that the data was based on measurements taken at one
point in time according to clinical indications and were assumed to
reflect their chronic condition. Moreover, our analysis of
cardiovascular risk factors is limited to hypertension and
overweight/obesity. Other cardiovascular risk factors such as
tobacco use, diabetes, physical activity and dietary factors were not
routinely collected during the clinical encounters during this time
period. In addition, measurement of blood cholesterol was usually
performed as clinically indicated and only on a small portion of
patients. Hypertension, however, is the most important risk factor
for myocardial infarction among Africans [43] and actionable
information on the prevalence of hypertension among HIV+
individuals in Africa has been lacking. This information is critical if
we are to expand health care systems in sub-Saharan Africa and
create stronger interactions with existing major global HIV
initiatives. A recent Institute of Medicine report calls for such
approaches that dovetail with current efforts to transition from
costly, disease-specific approaches toward more efficient ap-
proaches that promote better primary health care to meet a
range of health needs [44].
In conclusion, much of the literature surrounding cardiovascu-
lar disease among HIV+ patients in sub-Saharan Africa has
focused on infectious and inflammatory manifestations of HIV-
associated cardiac disease. There are, however, good reasons to
expect a transition in the magnitude of degenerative cardiovascu-
lar disease among HIV+ patients in sub-Saharan Africa. These
reasons include the changing patterns of traditional cardiovascular
risk factors in the region, ageing of the population, urbanization,
and increasing prolonged exposure to ART. This analysis has
shown that hypertension and obesity are already highly prevalent
among HIV+ patients in Western Kenya. The public policy
implications are great. There is a mismatch between aggregate
spending for global health and overall disease burden, whereby the
least amount of spending goes towards non-communicable
diseases despite these diseases contributing to the largest number
of disability adjusted life-years and overall mortality [45]. One
approach to address this discordance is by expanding the scope of
HIV care programs to recognize the important overlap between
communicable and noncommunicable diseases [46]. Programs in
sub-Saharan Africa that focus solely on HIV care are missing a
major opportunity to improve population health status at a
substantial future cost.
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